Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

被引：5
|
作者：
Cao, Yi [1 ,2 ]
Li, Yunjin [1 ,2 ]
Liu, Ruijie [1 ]
Zhou, Jianhua [1 ,2 ]
Wang, Kuansong [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China
[2] Cent South Univ, Sch Basic Med Sci, Dept Pathol, Changsha 410008, Peoples R China
来源：
CANCERS | 2023年 / 15卷 / 09期
基金：
中国国家自然科学基金;
关键词：
HER2-positive breast cancer; targeted therapy; resistance; anti-resistance; TRASTUZUMAB RESISTANCE; PROMOTES RESISTANCE; MONOCLONAL-ANTIBODY; SPLICE VARIANT; PHASE-II; HER2; GROWTH; EXPRESSION; LAPATINIB; CELLS;
D O I：
10.3390/cancers15092568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15-30% of breast cancers. In HER2positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental mechanisms of drug resistance in the targeted therapies of HER2positive breast cancer and summarizes recent research progress in this field, including preclinical and basic research studies.
引用
收藏
页数：27
相关论文
共 50 条
  • [21] Targeted therapy in HER2-positive breast cancer (Review)
    Li, Shu Guang
    Li, Li
    BIOMEDICAL REPORTS, 2013, 1 (04) : 499 - 505
  • [22] HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
    Xu, Luying
    Xie, Yuxin
    Gou, Qiheng
    Cai, Rui
    Bao, Rong
    Huang, Yucheng
    Tang, Ruisi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumabresistance in HER2-positive breast cancer
    Qiu, Yan
    Yang, Libo
    Liu, Honghong
    Luo, Xiaobo
    STEM CELLS, 2021, 39 (09) : 1125 - 1136
  • [24] Targeted therapies of HER2-positive gastric adenocarcinoma
    Schulze, Arik Bernard
    Kerkhoff, Andrea
    Lenz, Georg
    Kessler, Torsten
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S177 - S180
  • [25] Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
    Wong, Andrea L. A.
    Lee, Soo-Chin
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [26] HER2-targeted Therapeutic Strategies for HER2-positive Metastatic Breast Cancers
    Fujii, Teruhiko
    Miwa, Keisuke
    Ushijima, Tomoyuki
    Matsunaga, Mototsugu
    Fukahori, Masaru
    Yuge, Kotaro
    Toh, Uhi
    Iwakuma, Nobutaka
    Takahashi, Ryuji
    Takahashi, Hiroki
    Takenaka, Miki
    Mishima, Mai
    Akagi, Yoshito
    Kage, Masayoshi
    Nakagawa, Shino
    CURRENT CANCER THERAPY REVIEWS, 2014, 10 (03) : 225 - 233
  • [27] New therapeutic strategies in HER2-positive breast cancer
    Mery, Benoite
    Toussaint, Philippe
    Heudel, Pierre-Etienne
    Dufresne, Armelle
    Carbonnaux, Melodie
    Vanacker, Helene
    Bachelot, Thomas
    Tredan, Olivier
    BULLETIN DU CANCER, 2021, 108 (11) : S44 - S54
  • [28] TNFα induces multiresistance to HER2-targeted TNFα induces multiresistance to HER2-targeted therapies in HER2-positive breast cancer
    Mercogliano, Maria F.
    De Martino, Mara
    Bruni, Sofia
    Venturutti, Leandro
    Rivas, Martin
    Amasino, Matias
    Proietti, Cecilia J.
    Elizalde, Patricia V.
    Schillaci, Roxana
    CANCER RESEARCH, 2017, 77
  • [29] HER2-positive breast cancer: Current treatment strategies
    Perez, Edith A.
    Baweja, Mansoina
    CANCER INVESTIGATION, 2008, 26 (06) : 545 - 552
  • [30] Dual HER2-targeted approaches in HER2-positive breast cancer
    Ahn, Eugene R.
    Vogel, Charles L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 371 - 383
12345